查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086220

肽類藥物市場：2026-2032年全球市場預測（按肽類型、合成技術、給藥途徑、應用和最終用戶分類）

Peptide Therapeutics Market by Peptide Type, Synthesis Technology, Route Of Administration, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，胜肽類藥物市場將成長至 2,289.7 億美元，複合年成長率為 7.44%。

主要市場統計數據
基準年 2025 1384.9億美元
預計年份：2026年 1484.7億美元
預測年份 2032 2289.7億美元
複合年成長率 (%) 7.44%

肽類藥物正從小眾藥物類別轉變為代謝性疾病、腫瘤、內分泌疾病、罕見疾病和感染疾病研究領域的策略性成長引擎。其臨床價值建立在成熟的藥理學基礎之上：肽類藥物能以高度特異性結合靶點，發揮可預測的受體介導活性，並能彌合小分子藥物和生物製藥之間的治療差距。

GLP-1受體促效劑在全球廣泛的應用、胰島素類似物的持續使用、胜肽受體放射性核種療法的進展，以及口服長效細胞滲透性肽製劑研發管線的不斷拓展，進一步增強了胜肽類藥物的商業性和臨床應用勢頭。對產業領導者而言，胜肽類藥物市場正日益受到胜肽合成、製劑科學、藥物傳遞、分析表徵和可擴展生產品質等方面創新技術的影響。

肽類藥物前景的變革性變化

胜肽類藥物領域正受到三大因素的重塑：新一代遞送系統、生產過程現代化、治療領域拓展至傳統內分泌適應症之外。利用長效注射劑、緩釋製劑、脂化、環化、滲透促進劑和奈米顆粒等遞送技術，正在提升給藥的便利性、穩定性以及患者依從性。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過改進序列設計、結構預測、標靶檢驗、毒性篩檢和可行性評估，加速了胜肽類藥物的研發。 AI 模型有助於在進行昂貴的實驗室測試之前，優先篩選出具有高結合親和性、更強的抗蛋白水解穩定性、更低的免疫抗原性風險和更佳藥代動力學特徵的候選胜肽。

對關鍵區域的洞察

北美憑藉其活躍的生物製藥研發、豐富的FDA監管經驗、創業投資資金、學術研究的臨床應用以及代謝疾病、糖尿病、肥胖症和癌症治療的高普及率，仍然是肽類藥物治療領域的領先地區。歐洲則憑藉其成熟的臨床研究網路、EMA（歐洲藥品管理局）的監管、先進的GMP生產能力以及在德國、法國、義大利、西班牙和英國的積極佈局，為創新胜肽類藥物的研發和高品質的生產標準提供了有力支持。

關鍵群體特定見解

在東協地區，醫療保險覆蓋範圍的擴大、醫療旅遊的興起、本地化生產以及臨床研究參與度的提高，都催生了對價格合理的胜肽類藥物和研發夥伴關係的需求。在海灣合作理事會（GCC）市場，專科藥物、糖尿病管理、肥胖症治療和先進的醫院系統是優先發展方向，而基於胜肽的代謝和內分泌療法在公共衛生策略中佔據著尤為重要的地位。

主要國家的概況

美國正透過FDA的批准、學術界與生物技術公司的合作、先進的臨床試驗基礎設施以及對GLP-1、胰島素類似物、癌症治療和罕見疾病治療的強勁需求，推動肽類藥物的創新。加拿大支持臨床研究、提供專科醫療服務以及加強生技藥品的監管能力。同時，墨西哥和巴西是拉丁美洲的關鍵市場，糖尿病治療不斷擴展，當地夥伴關係關係日益密切，慢性病治療的覆蓋範圍也越來越廣。

為行業領導者提供的實用建議

產業領導者應優先考慮差異化胜肽設計、可擴展生產和以患者為中心的給藥方法。投資長效製劑、口服胜肽技術、低溫運輸最佳化、自動注射器、植入式或緩釋製劑以及器械驅動的給藥方法，可以提高患者的用藥依從性、可及性和臨床效用。

調查方法

本執行摘要採用結構化的二手研究架構編寫，並遵循專業市場研究規範。分析整合了公開的監管資訊、臨床開發趨勢、藥品生產實踐、同行評審的科學文獻、專利和在研產品指標、最新的醫療政策動態以及宏觀層面的醫療指標。

結論

肽類療法已進入高價值發展階段，其特點是臨床特異性強、給藥方式改進、合成規模化以及在慢性病和特殊疾病中的應用不斷拓展。該領域不再局限於注射用內分泌藥物，而是涵蓋了多功能肽、定向放射性配體、候選抗生素、肽-藥物偶聯物以及精準定向療法。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 胜肽類藥物市場：依胜肽類型分類

  • 天然胜肽
    • 荷爾蒙衍生胜肽
    • 神經胜肽
  • 修飾胜肽
    • 環肽
    • 聚乙二醇化胜肽
    • 脂化胜肽
  • 功能性胜肽
    • 抗菌胜肽
    • 細胞滲透性肽

第8章 胜肽類治療藥物市場：依合成技術分類

  • 生物合成
  • 化學合成
    • 固相胜肽合成
    • 液相胜肽合成

第9章：胜肽類藥物治療市場：依給藥途徑分類

  • 腸外給藥
    • 肌肉內部
    • 靜脈
    • 皮下
  • 口服/非注射給藥
    • 口服
    • 鼻內
    • 肺部給藥
    • 經皮給藥

第10章：胜肽類治療藥物市場：依應用領域分類

  • 心血管疾病
    • 心臟衰竭
    • 高血壓
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染疾病
  • 代謝性疾病
    • 糖尿病
    • 肥胖
    • 內分泌疾病
  • 腫瘤學
    • 乳癌
    • 肺癌
    • 黑色素瘤

第11章 胜肽類治療市場：依最終用戶分類

  • 診所
  • 醫院
  • 研究機構

第12章 胜肽類治療藥物市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 胜肽類治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 胜肽類治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AmbioPharm Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Aurigene Pharmaceutical Services Limited
  • Bachem Holding AG
  • Bicycle Therapeutics plc
  • Bristol-Myers Squibb Company
  • CordenPharma International GmbH
  • CSBio Inc.
  • Cybrexa Therapeutics, Inc.
  • Eli Lilly and Company
  • Ferring Pharmaceuticals A/S
  • GlaxoSmithKline PLC
  • Ipsen SA
  • Ironwood Pharmaceuticals, Inc.
  • Mainline Biosciences LLC
  • Novartis AG
  • Novo Nordisk A/S
  • Oncopeptides AB
  • Peptech Biosciences Ltd.
  • Peptide Institute, Inc.
  • PeptiDream Inc.
  • PolyPeptide Group AG
  • Protagonist Therapeutics, Inc.
  • Sanofi SA
  • SELLAS Life Sciences Group, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Zealand Pharma A/S
Product Code: MRR-030EE4851583

The Peptide Therapeutics Market is projected to grow by USD 228.97 billion at a CAGR of 7.44% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 138.49 billion
Estimated Year [2026] USD 148.47 billion
Forecast Year [2032] USD 228.97 billion
CAGR (%) 7.44%

Peptide therapeutics have moved from a specialized drug class into a strategic growth engine for metabolic disease, oncology, endocrinology, rare diseases, and infectious disease research. Their clinical value is supported by established pharmacology: peptides can bind targets with high specificity, offer predictable receptor-mediated activity, and bridge the therapeutic gap between small molecules and biologics.

Commercial and clinical momentum is being reinforced by the global adoption of GLP-1 receptor agonists, continued use of insulin analogs, advances in peptide receptor radionuclide therapy, and expanding pipelines in oral, long-acting, and cell-penetrating peptide formats. For industry leaders, the peptide therapeutics market is increasingly defined by innovation in peptide synthesis, formulation science, drug delivery, analytical characterization, and scalable manufacturing quality.

Transformative Shifts in the Peptide Therapeutics Landscape

The peptide therapeutics landscape is being reshaped by three forces: next-generation delivery systems, manufacturing modernization, and therapeutic expansion beyond traditional endocrine indications. Long-acting injectables, depot formulations, lipidation, cyclization, permeation enhancers, and nanoparticle-enabled delivery are improving dosing convenience, stability, and patient adherence.

At the same time, solid-phase peptide synthesis, liquid-phase hybrid approaches, greener solvents, continuous manufacturing concepts, high-resolution analytics, and advanced purification technologies are improving scalability and product consistency. The competitive frontier is also shifting toward multi-receptor agonists, peptide-drug conjugates, targeted radioligands, antimicrobial peptides, and peptides designed for intracellular signaling pathways or protein-protein interaction targets.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating peptide therapeutics by improving sequence design, structure prediction, target validation, toxicity screening, and developability assessment. AI-enabled models can help prioritize peptide candidates with stronger binding affinity, improved proteolytic stability, lower immunogenicity risk, and more favorable pharmacokinetic profiles before costly wet-lab testing.

The most important cumulative impact is speed and selectivity across discovery and development. AI, machine learning, and generative design are reducing discovery cycles while supporting formulation screening, synthetic route optimization, impurity prediction, and clinical trial stratification. However, responsible adoption depends on high-quality datasets, validated models, regulatory transparency, data governance, and expert human review to ensure reproducibility and patient safety.

Key Regional Insights

North America remains a leading region for peptide therapeutics due to strong biopharmaceutical R&D, established FDA regulatory experience, venture financing, academic translation, and high uptake of metabolic, diabetes, obesity, and oncology therapies. Europe benefits from mature clinical research networks, EMA oversight, advanced GMP manufacturing capabilities, and strong activity across Germany, France, Italy, Spain, and the United Kingdom, supporting both innovative peptide drug development and high-quality production standards.

Asia-Pacific is expanding rapidly as China, India, Japan, South Korea, and Australia invest in biosciences, contract development and manufacturing, clinical trial capacity, and advanced bioprocessing infrastructure. Latin America is gaining relevance through Brazil and Mexico as access to diabetes, obesity, and specialty care improves, while the Middle East is strengthening tertiary care, precision medicine programs, and hospital-based specialty treatment. Africa presents long-term demand linked to rising noncommunicable disease burden, infectious disease needs, and healthcare access initiatives, although affordability, cold-chain infrastructure, and regulatory capacity remain important adoption factors.

Key Group Insights

Within ASEAN, expanding healthcare coverage, medical tourism, regional manufacturing, and growing clinical research participation are creating demand for affordable peptide medicines and development partnerships. GCC markets are prioritizing specialty care, diabetes management, obesity treatment, and advanced hospital systems, making peptide-based metabolic and endocrine therapies particularly relevant to public health strategies.

The European Union remains influential through centralized regulatory pathways, research funding, pharmacovigilance standards, and quality frameworks that shape global peptide manufacturing. BRICS countries are important for scale, cost-efficient production, large patient populations, and high disease burden, particularly in diabetes, oncology, and cardiovascular-metabolic disorders. G7 markets lead premium innovation, reimbursement influence, and advanced clinical adoption, while NATO-aligned countries increasingly emphasize resilient pharmaceutical supply chains, biomedical preparedness, and secure access to critical medicines.

Key Country Insights

The United States leads peptide therapeutics innovation through FDA approvals, academic-biotech translation, advanced clinical trial infrastructure, and strong demand for GLP-1, insulin analog, oncology, and rare disease therapies. Canada supports clinical research, specialty access, and biologics-focused regulatory capabilities, while Mexico and Brazil are important Latin American markets for diabetes treatment expansion, local partnerships, and broader access to chronic disease therapies.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced healthcare systems, reimbursement frameworks, hospital networks, and strong clinical trial activity, while Russia remains a large pharmaceutical market with localization and access considerations. China and India are scaling peptide manufacturing, active pharmaceutical ingredient capacity, and R&D programs; Japan emphasizes high-quality innovation, aging-related therapeutic demand, and stringent regulatory science; South Korea is advancing biopharma platforms and precision medicine capabilities; and Australia is recognized for early-phase clinical research strength, regulatory efficiency, and academic clinical trial networks.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated peptide design, scalable manufacturing, and patient-centered delivery. Investments in long-acting formulations, oral peptide technologies, cold-chain optimization, autoinjectors, implantable or depot systems, and device-enabled administration can improve adherence, access, and clinical utility.

Organizations should strengthen AI-enabled discovery, secure high-purity raw material supply, diversify CDMO partnerships, and build regulatory evidence early around safety, immunogenicity, stability, impurities, bioanalytical performance, and comparability. Commercial teams should align access strategies with real-world evidence and outcomes data, especially in obesity, diabetes, oncology, and rare diseases where payer scrutiny, adherence evidence, and long-term safety monitoring are increasingly important.

Research Methodology

This executive summary is developed using a structured secondary research framework aligned with professional market intelligence practices. The analysis synthesizes publicly available regulatory information, clinical development trends, pharmaceutical manufacturing practices, peer-reviewed scientific literature, patent and pipeline indicators, healthcare policy updates, and macro-level healthcare indicators.

Insights are validated through triangulation across therapeutic area adoption, regional healthcare infrastructure, regulatory activity, drug development trends, manufacturing dynamics, and supply chain considerations. The methodology emphasizes data integrity, source reliability, market relevance, and practical decision support while avoiding unsupported projections, unverified claims, market estimation, market sizing, market share, or forecasting.

Conclusion

Peptide therapeutics are entering a high-value phase defined by clinical specificity, improved delivery, scalable synthesis, and expanding use across chronic and specialty diseases. The field is no longer limited to injectable endocrine drugs; it now includes multi-functional peptides, targeted radioligands, antimicrobial candidates, peptide-drug conjugates, and precision-targeted modalities.

Organizations that combine AI-enabled discovery, robust manufacturing, regulatory discipline, quality-by-design principles, and access-focused commercialization will be best positioned to lead. As demand rises across established and emerging healthcare systems, peptide therapeutics will remain a critical pillar of next-generation pharmaceutical innovation and precision medicine.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Peptide Therapeutics Market, by Peptide Type

  • 7.1. Native Peptides
    • 7.1.1. Hormonal Peptides
    • 7.1.2. Neuropeptides
  • 7.2. Modified Peptides
    • 7.2.1. Cyclized Peptides
    • 7.2.2. PEGylated Peptides
    • 7.2.3. Lipidated Peptides
  • 7.3. Functional Peptides
    • 7.3.1. Antimicrobial Peptides
    • 7.3.2. Cell Penetrating Peptides

8. Peptide Therapeutics Market, by Synthesis Technology

  • 8.1. Biological Synthesis
  • 8.2. Chemical Synthesis
    • 8.2.1. Solid Phase Peptide Synthesis
    • 8.2.2. Liquid Phase Peptide Synthesis

9. Peptide Therapeutics Market, by Route Of Administration

  • 9.1. Parenteral
    • 9.1.1. Intramuscular
    • 9.1.2. Intravenous
    • 9.1.3. Subcutaneous
  • 9.2. Non Parenteral
    • 9.2.1. Oral
    • 9.2.2. Nasal
    • 9.2.3. Pulmonary
    • 9.2.4. Transdermal

10. Peptide Therapeutics Market, by Application

  • 10.1. Cardiovascular Diseases
    • 10.1.1. Heart Failure
    • 10.1.2. Hypertension
  • 10.2. Infectious Diseases
    • 10.2.1. Bacterial Infections
    • 10.2.2. Viral Infections
  • 10.3. Metabolic Disorders
    • 10.3.1. Diabetes
    • 10.3.2. Obesity
    • 10.3.3. Endocrine Disorders
  • 10.4. Oncology
    • 10.4.1. Breast Cancer
    • 10.4.2. Lung Cancer
    • 10.4.3. Melanoma

11. Peptide Therapeutics Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals
  • 11.3. Research Institutes

12. Peptide Therapeutics Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Peptide Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Peptide Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AmbioPharm Inc.
  • 16.2. Amgen Inc.
  • 16.3. AstraZeneca PLC
  • 16.4. Aurigene Pharmaceutical Services Limited
  • 16.5. Bachem Holding AG
  • 16.6. Bicycle Therapeutics plc
  • 16.7. Bristol-Myers Squibb Company
  • 16.8. CordenPharma International GmbH
  • 16.9. CSBio Inc.
  • 16.10. Cybrexa Therapeutics, Inc.
  • 16.11. Eli Lilly and Company
  • 16.12. Ferring Pharmaceuticals A/S
  • 16.13. GlaxoSmithKline PLC
  • 16.14. Ipsen S.A.
  • 16.15. Ironwood Pharmaceuticals, Inc.
  • 16.16. Mainline Biosciences LLC
  • 16.17. Novartis AG
  • 16.18. Novo Nordisk A/S
  • 16.19. Oncopeptides AB
  • 16.20. Peptech Biosciences Ltd.
  • 16.21. Peptide Institute, Inc.
  • 16.22. PeptiDream Inc.
  • 16.23. PolyPeptide Group AG
  • 16.24. Protagonist Therapeutics, Inc.
  • 16.25. Sanofi S.A.
  • 16.26. SELLAS Life Sciences Group, Inc.
  • 16.27. Takeda Pharmaceutical Company Limited
  • 16.28. Teva Pharmaceutical Industries Ltd
  • 16.29. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEPTIDE THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PEPTIDE THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEPTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NATIVE PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NATIVE PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NATIVE PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HORMONAL PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HORMONAL PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HORMONAL PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROPEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEUROPEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROPEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MODIFIED PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MODIFIED PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MODIFIED PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CYCLIZED PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CYCLIZED PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CYCLIZED PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PEGYLATED PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEGYLATED PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PEGYLATED PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIPIDATED PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LIPIDATED PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIPIDATED PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FUNCTIONAL PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FUNCTIONAL PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FUNCTIONAL PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELL PENETRATING PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL PENETRATING PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELL PENETRATING PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICAL SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICAL SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICAL SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHEMICAL SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHEMICAL SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHEMICAL SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SOLID PHASE PEPTIDE SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SOLID PHASE PEPTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SOLID PHASE PEPTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIQUID PHASE PEPTIDE SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LIQUID PHASE PEPTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIQUID PHASE PEPTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NON PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PULMONARY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PULMONARY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PULMONARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HEART FAILURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEART FAILURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HYPERTENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HYPERTENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL OBESITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL OBESITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL OBESITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ENDOCRINE DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENDOCRINE DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ENDOCRINE DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. GCC PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 244. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 245. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 246. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 248. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 250. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 251. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 253. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 254. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 255. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. G7 PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 292. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 293. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 294. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 296. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 298. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 299. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 300. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 301. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 302. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 303. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 304. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 305. NATO PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 308. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 309. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 310. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 312. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 313. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 314. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 315. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 316. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 317. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 318. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 319. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 320. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 335. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 336. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 337. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 338. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 339. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 340. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 341. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 342. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 343. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 344. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 345. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 346. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 347. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 348. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 349. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 350. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 351. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 352. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 353. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 354. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 355. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 356. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 357. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 358. MEXICO